Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Un essai clinique du traitement KVA12123 seul et en association avec le pembrolizumab dans les tumeurs solides avancées (VISTA-101)

30 septembre 2026 mis à jour par: Kineta Inc.

A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

The study sought to assess the safety of KVA12123 [TBS-2025] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.

Aperçu de l'étude

Description détaillée

This was a first-in-human (FIH), Phase 1/2, open-label, multicenter, dose escalation, and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123, subsequently designated TBS-2025, alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study was planned to conduct in 4 planned parts: Parts A and B focus on dose escalation (single-agent and in combination), and Parts C and D focus on dose expansion (single-agent and in combination).

Parts A (single-agent KVA12123) and B (KVA12123 + pembrolizumab) allowed up to 10 dose escalation cohorts: 6 in Part A and 4 in Part B, with 1 to 6 participants per cohorts. These parts were intended to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary tumor response, and to inform the selection of recommended phase 2 doses.

Parts C (single-agent KVA12123) and D (KVA12123 + pembrolizumab) were planned but not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

Type d'étude

Interventionnel

Inscription (Réel)

40

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Santa Monica, California, États-Unis, 90404
        • UCLA Health (Santa Monica Cancer Care)
    • Colorado
      • Denver, Colorado, États-Unis, 80218
        • Sarah Cannon Research Institute at HealthONE
    • Florida
      • Sarasota, Florida, États-Unis, 34232
        • Sarah Cannon Research Institute at Florida Cancer Specialists
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • University of Michigan
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19107
        • Thomas Jefferson University
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37203
        • Sarah Cannon Research Institute at Tennessee Oncology
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Fred Hutchinson Cancer Research Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria

  1. Willing and able to provide informed consent.

  2. Be at least 18 years of age at the time of consent.

  3. Has histologically or cytologically confirmed, locally advanced or metastatic solid tumor that has progressed or was non-responsive to standard of care therapy and for which no available curative therapy exists.

  4. Has expected survival ≥16 weeks.

  5. Presence of measurable disease by iRECIST.

  6. Has an ECOG performance status score of 0 or 1.

  7. Has adequate organ function within 10 days prior to the start of study treatment.

  8. Has normal thyroid function or hypothyroid with stable supplementation.

  9. Has consented to the collection of archival tissue prior to study treatment initiation.

  10. Participants with prior exposure to systemic anticancer therapy including investigational agents following a 4-week washout period are eligible. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.

  11. Participants having prior curative radiation therapy completed 2 weeks prior to study drug administration or prior palliative radiation therapy to non-CNS disease completed at least 1 week prior to study drug administration are eligible.

  12. HIV-infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease.

  13. Participants with a history of HBV infection having durable HBsAg loss and undetectable serum HBV DNA no longer requiring treatment are eligible.

  14. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening and participants have completed curative antiviral therapy.

  15. Post-menopausal women and surgically sterile men and women are permitted.

  16. Patients of childbearing potential are permitted to participate under the following conditions:

    1. Must have negative urine pregnancy test result within 72 hrs prior to the first dose of any study drug
    2. Must agree not to become pregnant during the study and for 120 days after the final dose of any study drug
    3. Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 120 days after the final dose of any study drug
    4. If sexually active in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  17. Patients who can father children are permitted to participate under the following conditions:

    1. Must agree not to donate sperm starting at the time of informed consent and continuing throughout the study period and for 120 days after the final dose of any study drug
    2. If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at the time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug
    3. If sexually active with a person who is pregnant or breastfeeding, must consistently use a condom starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  18. Must be willing and able to comply with the trial procedures and the follow-up schedule.

Exclusion Criteria

  1. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression.
  2. Concurrent cancer other than disease under study requiring systemic treatment. Participants with basal cell or squamous cell skin cancer treated with curative intent, carcinoma in-situ of the cervix or breast treated with curative intent, RAI stage 0 Chronic Lymphocytic Leukemia, monoclonal gammopathy of undetermined significance, superficial bladder cancer or very low and low risk prostate cancer (localized Gleason score ≤ 6) under active surveillance are eligible.
  3. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
  4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg QD of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
  5. History of (non-infectious) pneumonitis/interstitial lung disease (ILD) that required steroids or current pneumonitis/ILD.
  6. Prior treatment with VISTA-targeted therapy.
  7. Prior history of allogeneic, solid organ or stem cell transplant, or adoptive T-cell transplant.
  8. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, LAG-3, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).
  9. Active known or suspected autoimmune disease that has required systemic treatment within the past year. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Prior systemic anticancer therapy, including investigational agents, within 4 weeks of treatment. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.
  11. Has received prior radiation therapy within 2 weeks of start of study treatment or has a history of radiation pneumonitis.
  12. Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
  13. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
  14. Any requirement for daily supplemental oxygen.
  15. Any condition requiring systemic treatment with corticosteroids (>10 mg QD prednisone equivalents) or other immunosuppressive medications within 14 days before the first dose of study drug.
  16. Serious or poorly controlled cardiovascular disease.
  17. Chronic hepatitis B or C.
  18. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  19. Has an active infection requiring systemic therapy.
  20. Known active or latent tuberculosis.
  21. If the participant had major surgery, must have recovered adequately from the procedure and/or any complications.
  22. Toxicities arising from prior cancer therapy that have not resolved to Grade 1 or baseline.
  23. Red blood cell or platelet infusion within the preceding 2 weeks.
  24. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  25. Known hypersensitivity to any excipient contained in the drug formulation of KVA12123.
  26. Any significant history of drug allergy as assessed by the investigator.
  27. Positive urine pregnancy test within 72 hrs of study drug administration.
  28. Participants who are breastfeeding, pregnant, or planning to become pregnant from time of informed consent until at least 120 days after final dose of study drug.
  29. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
  30. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  31. Inability to comply with study procedures.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: KVA12123 [TBS-2025] Monotherapy Dose Escalation

Part A will consist of dose escalation with KVA12123 [TBS-2025] administered as a single agent in participants with advanced solid tumors.

Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.

Expérimental: KVA12123 [TBS-2025] Plus Pembrolizumab Dose Escalation

Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.

Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

Autres noms:
  • Keytruda
Expérimental: KVA12123 [TBS-2025] Monotherapy Dose Expansion

Part C will consist of dose expansion with KVA12123 [TBS-2025] administered as a single agent at the RP2D in participants with advanced solid tumors. Part C was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.

Expérimental: KVA12123 Plus Pembrolizumab Dose Expansion

Part D will consist of dose expansion with KVA12123 [TBS-2025] administered at the RP2D in combination with a fixed dose of pembrolizumab. Part D was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

Autres noms:
  • Keytruda

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adverse Events
Délai: Through study completion, an average of 1 year

Type and frequency of adverse events as assessed by CTCAE v5.0.

Through study completion, an average of 1 year
AEs related to study drug
Délai: Through study completion, an average of 1 year

Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.

Through study completion, an average of 1 year
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
Délai: Through study completion, an average of 1 year

Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).

Through study completion, an average of 1 year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Pharmacokinetic (PK) profile of KVA12123 (Cmax)
Délai: Through study completion, an average of 1 year

maximum serum concentration (micrograms/milliliter [mL])

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cmin)
Délai: Through study completion, an average of 1 year

trough serum concentration (micrograms/mL)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (tmax)
Délai: Through study completion, an average of 1 year

time to maximum serum concentration (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (AUC)
Délai: Through study completion, an average of 1 year

Area under the concentration-time curve (microgram*mL/hour)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (t1/2)
Délai: Through study completion, an average of 1 year

Elimination half life (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Vd)
Délai: Through study completion, an average of 1 year

Volume of distribution (milliliter or liter)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cl)
Délai: Through study completion, an average of 1 year

Clearance (mL/hour)

Through study completion, an average of 1 year
Concentration of anti-KVA12123 antibodies in serum
Délai: Through study completion, an average of 1 year

Change from baseline in anti-KVA12123 antibodies in serum (antibody concentration per mL)

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123 in combination with pembrolizumab
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123 plus pembrolizumab
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123 plus pembrolizumab
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123 plus pembrolizumab
Délai: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Thierry Guillaudeux, PhD, Kineta Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

3 mars 2023

Achèvement primaire (Réel)

16 octobre 2025

Achèvement de l'étude (Réel)

18 décembre 2025

Dates d'inscription aux études

Première soumission

9 décembre 2022

Première soumission répondant aux critères de contrôle qualité

24 janvier 2023

Première publication (Réel)

1 février 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • VISTA-101
  • KEYNOTE-E67 (Autre identifiant: Merck, Sharp & Dohme, LLC)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner